Business
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a review of recent accomplishments and anticipated upcoming developments.
About this update from Biohaven Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026.","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"Advancement of high-value, late-stage priority programs:","length":56,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal epilepsy program with selective Kv7 ion channel activator, opakalim, with expected topline results in 2H 2026.","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 2 obesity study with myostatin-activin pathway inhibitor, taldefgrobep alfa, completed enrollment and topline data expected in 2H 2026.","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"TRAP™ and MoDE™ Degraders Advancing to Pivotal Trials","length":53,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal trials in both IgA nephropathy (IgAN) with Gd-IgA1 TRAP degrader, BHV-1400, and Graves' disease with IgG MoDE degrader, BHV-1300, expected to initiate by mid-year.","length":180,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":180,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":492,"olType":false}]},{"val":[{"type":"text","content":"Sustained progress across development pipeline: ","length":47,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment in Phase 2 early Parkinson's disease trial with brain-penetrant TYK2/JAK1 inhibitor, BHV-8000, continues to advance.","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Enrollment advances in advanced endometrial cancer expansion cohort with the next-generation TROP-2 directed ADC BHV-1510 in combination with Libtayo®.","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Dose escalation advances with BHV-1530, a first-in-class FGFR3-directed antibody-drug conjugate (ADC). No dose-limiting toxicities observed to date.","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":435,"olType":false}]},{"val":[{"type":"text","content":"A total of 5 abstracts, including 1 oral presentation and 4 posters, featured at the American Academy of Neurology ("AAN") Annual Meeting","length":147,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Highl...